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ABSTRACT
Objective: To inform the design of a randomised
controlled trial (called EcLiPSE) to improve the
treatment of children with convulsive status epilepticus
(CSE). EcLiPSE requires the use of a controversial
deferred consent process.
Design: Qualitative interview and focus group study.
Setting: 8 UK support groups for parents of children
who have chronic or acute health conditions and
experience of paediatric emergency care.
Participants: 17 parents, of whom 11 participated in
telephone interviews (10 mothers, 1 father) and 6 in a
focus group (5 mothers, 1 father). 6 parents (35%)
were bereaved and 7 (41%) had children who had
experienced seizures, including CSE.
Results: Most parents had not heard of deferred
consent, yet they supported its use to enable the
progress of emergency care research providing a
child’s safety was not compromised by the research.
Parents were reassured by tailored explanation, which
focused their attention on aspects of EcLiPSE that
addressed their priorities and concerns. These aspects
included the safety of the interventions under
investigation and how both EcLiPSE interventions are
used in routine clinical practice. Parents made
recommendations about the appropriate timing of a
recruitment discussion, the need to individualise
approaches to recruiting bereaved parents and the use
of clear written information.
Conclusions: Our study provided information to help
ensure that a challenging trial was patient centred in its
design. We will use our findings to help EcLiPSE
practitioners to: discuss potentially threatening trial
safety information with parents, use open-ended
questions and prompts to identify their priorities and
concerns and clarify related aspects of written trial
information to assist understanding and decision-
making.
BACKGROUND
The design of research studies often requires
a balance to be struck between what is
ethically and pragmatically acceptable and
what is scientiﬁcally ideal.1–3 Qualitative
research has a potential role to inform this
balance, particularly in challenging settings
where some trials might otherwise be
regarded as being too problematic to
conduct. For example, in paediatric settings,
there are relatively few clinical trials to
inform the development of emergency care
Strengths and limitations of this study
▪ This is the first study to provide detailed insight
into how parents perceive deferred consent in
the challenging paediatric emergency care
setting. Practitioners can use the findings to
assist parental understanding and decision-
making by discussing potentially threatening trial
safety information with parents and using open-
ended questions and prompts to identify and
discuss their priorities and concerns.
▪ Our interview and focus group study involved
parents of children with a range of acute and
chronic health conditions who had experience of
the emergency care setting. The findings are
therefore potentially transferable to other trials
that propose a deferred consent approach in
paediatric emergency care.
▪ Our findings demonstrate the value of using
qualitative methods at the pre-trial stage to make
clinical trials more patient centred and to provide
evidence to help challenge assumptions about
approaches to consent that might otherwise go
unchallenged.
▪ The proposed trial (called EcLiPSE) was hypo-
thetical and not all parents in our sample had
children who had experienced the particular con-
dition that is the focus of the trial. Our sample is
also likely to comprise parents with an interest in
research, which may not reflect the target
EcLiPSE sample.
▪ Children were not involved in our study.
Research is required to explore their perceptions
of deferred consent in emergency care trials.
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interventions to save the lives of children.4 Paediatric
accident and emergency care trials are fraught with
ethical and practical difﬁculties.5 Freely given informed
consent of a patient before any research procedures are
implemented is a key principle of good clinical practice
to protect patient rights, safety and well-being.6 7 The
process of informed consent requires an exchange of
information with ‘ample time and opportunity to
inquire about details of the trial and decide whether or
not to participate in the trial’.8 This information
exchange is often impossible in the emergency care
setting, where seeking prospective consent would delay
the administration of time-critical interventions.
Moreover, the delays needed to fulﬁl requirements for
informed consent may reduce the effect of any interven-
tions.9 As children (<16 years) cannot legally provide
consent for a trial of investigational medicinal products,
informed consent in this setting refers to the ‘proxy’
consent that is sought from parents or legal guardians.
Even when interventions in the emergency setting are
not so time-critical, there are ethical concerns about the
quality of parental informed consent, as their capacity to
understand trial information is likely to be compromised
by the stressful situation.4 10 In 2008, UK legislation was
amended to address such issues by enabling consent to
be deferred in children’s clinical trials11 when the fol-
lowing conditions are met: (1) treatment is required
urgently; (2) urgent action is required for the purposes
of the trial; (3) it is not reasonably practicable to obtain
consent prospectively and (4) an ethics committee has
given approval to the procedure under which the action
is taken. Consent for the child’s participation in the trial
can therefore be sought from parents or legal guardians
after his/her enrolment and the administration of trial
interventions. In this situation, consent is being sought
for the child to continue in the trial and for his/her
data to be retained and included in the analyses.11 12
Despite legislation enabling deferred consent, its use
remains controversial. Patients in such trials do not have
an opportunity to veto the investigational interventions
because these will have already been performed by the
time deferred consent is sought.13 14 Internationally,
there is a lack of research that describes public attitude
towards deferred consent13 and how to make it appropri-
ate to the needs of parents, children and practitioners. A
trial conducted almost a decade ago compared the effect-
iveness of buccal midazolam versus rectal diazepam for
the emergency treatment of status epileptics in chil-
dren.15 As it was not deemed appropriate to seek consent
from a parent while their child was in a tonic–clonic
seizure, consent was deferred until as soon as practically
possible after treatment. Consultation took place as part
of the trial to explore the acceptability of deferred
consent with participating families, although the ﬁndings
of this consultation were never reported. Researchers in
the USA using research consent waivers16 are required to
use a community consultation approach whereby the
researchers are required to consult with representatives
of the community from which participants are derived, as
well as post public notices of the study protocol, risks,
beneﬁts and results.16 17 However, the Food and Drug
Administration (FDA) has recently issued guidance on
conducting emergency research without consent18 in
response to varied practice, including wide variations in
the consultation methods used.19 20
Qualitative research may provide a more systematic
approach to consultation for emergency care trials; such
research can also facilitate exploration of public and
patient opinion to inform approaches to consent in the
emergency setting. Studies have shown how qualitative
research can inform trial development in challenging
settings, including the identiﬁcation of barriers and
potential solutions to successful recruitment21–23 and
acceptability of approaches to consent procedures.24 25
Historically, there has been a paucity of such research,
despite its potential to help trialists understand the com-
plexities and challenges arising from the social contexts
in which trials are based.26 A recent systematic mapping
review of qualitative research in the clinical trials setting
indicated27 that while such work had considerable
potential to inform trials, this potential is often lost
because the qualitative study ﬁndings are too late to
inform the partner trials. The reviewers argued that initi-
ating qualitative research at the design stage of partner
trials would help to increase the impact of this type of
work, thus beneﬁting trials and, ultimately, patients.28
We identiﬁed the need for a clinical trial to improve
the treatment of children suffering from convulsive
status epilepticus (CSE). CSE is the most common and
serious neurological emergency in children.29 30
Although there is a very low risk that children treated
for CSE will subsequently die (<1%),31 these children
are at increased risk of irreversible morbidity, including
chronic drug-resistant epilepsy and neurodisability
related not only to the condition and its cause but also
its management.32 The current management of CSE
depends on a national algorithm wherein two doses of a
benzodiazepine medication are administered initially.33
If the seizures continue, a second and longer acting anti-
convulsant is used. For many years this has been pheny-
toin, but there is no randomised controlled evidence to
support its use. There are several serious adverse effects
associated with phenytoin use including hypotension,
cardiac arrhythmias (which may prove fatal), hepatotox-
icity, phlebitis, severe tissue extravasation injury (the
‘purple glove syndrome’) and Steven Johnson’s syn-
drome.34 Intravenous levetiracetam has shown potential
to be a safe and effective alternative to phenytoin.35 36
Recent evidence has suggested that it not only termi-
nates CSE but can also be injected quicker, it has milder,
more transient side effects and does not have the
cardiac or hepatic toxicity seen with phenytoin.37 We
therefore designed EcLiPSE (Emergency use of
Levetiracetam vs Phenytoin in Status Epilepticus), an
unblinded pragmatic multicentre randomised trial to
compare two treatments (intravenous levetiracetam and
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intravenous phenytoin) for the termination of acute,
prolonged tonic–clonic seizures, including CSE in chil-
dren aged between 6 months and 18 years.
Challenges in conducting the trial were identiﬁed by
practitioners and patient public involvement (PPI) rep-
resentative within the trial team during the design stage
and included: a vulnerable target population (children
aged between 6 months and 18 years); the need for the
intervention to be delivered during a medical emer-
gency; insufﬁcient time to obtain informed consent
prior to the intervention and levetiracetam not being
the standard second-line anticonvulsant used to treat
status epilepticus. In addition, previous trials conducted
since the introduction of legislation enabling deferred
consent in paediatric trials11 have involved comparisons
of investigational interventions in current standard use.
EcLiPSE is breaking new ground in using deferred
consent within a trial that compares an established treat-
ment, with a treatment that is not yet in standard use.25
We reasoned that qualitative research could help us
identify how best to approach these challenges in a way
that was family-centred and ethically acceptable. We
designed our qualitative study to explore the views of
parents on EcLiPSE, our approach to seeking deferred
consent in the emergency care setting and the content
of the patient information sheet (PIS), with the aim of
using the ﬁndings to inform our deliberations on
EcLiPSE’s design and associated grant and research
ethics committee applications.
METHODS
We used a focus group and semistructured interviews
with parents of children with acute and chronic condi-
tions who had experience of their children being admit-
ted to a paediatric accident and emergency department
for urgent medical care. This work was conducted as
part of a wider study (called CONNECT) investigating
consent methods in paediatric and neonatal emergency
care trials.
The CONNECT advisory group and EcLiPSE trial
development team developed and reviewed an interview
topic guide and draft EcLiPSE PIS. The topic guide
covered key areas indicated within a review of the litera-
ture and previous CONNECT study ﬁndings25 and the
EcLiPSE trial team identiﬁed further topics pertinent to
this trial. Topics included: approaches to consent in the
emergency care setting; parental understanding and
decision-making; length and content of information pro-
vided in the PIS; trial design and acceptability of deferred
consent. We created a separate section of questions for
bereaved parents to explore their views and recommen-
dations on whether and how parents should be
approached about a clinical trial after a child’s death.
Children eligible to participate in EcLiPSE either have
chronic epilepsy and may be susceptible to CSE, or may
present with a ﬁrst prolonged tonic–clonic seizure. The
team agreed that it was important to ensure
participation of families who had experienced treatment
of this medical emergency as well as those without such
experience. We contacted a range of UK parent support
groups for parents of children with acute and chronic
conditions to request their help in identifying suitable
parents for our qualitative study. In addition, support
groups for bereaved parents and conditions associated
with CSE in children (eg, Dravet syndrome,
Lennox-Gastaut syndrome) were purposively sampled to
ensure that the views of such parents were included.38
Identiﬁed gatekeepers (eg, support group research coor-
dinators) were asked to send CONNECT invitations to
their members via email, or place the request on their
website or Facebook page. The inclusion criteria stated
that parents should have experience of paediatric emer-
gency care. Parents who registered an interest via email
were sent a CONNECT information sheet, consent form
and a copy of the EcLiPSE PIS. To acknowledge child-
care responsibilities and personal preference, we pro-
vided parents with the option to take part in a
telephone interview or focus group. Parents were asked
to indicate whether they were bereaved in order to tailor
the interview questions appropriately. We only asked
bereaved parents questions about approaches to consent
in EcLiPSE in the situation that a child had died; we felt
that it would be difﬁcult for non-bereaved parents to
understand the complexities of this situation and make
appropriate recommendations to inform trial protocol.
All interviews were semistructured using a topic guide
with open-ended questions and unstructured prompts to
facilitate free-ﬂowing conversation and explore unantici-
pated topics. Discussion was participant centred to
ensure that the content reﬂected their own priorities
and views on EcLiPSE rather than the researchers’.
KW conducted all interviews (including the focus
group) and led the analysis. The focus group and subse-
quent interview sessions were digitally audiorecorded,
transcribed and anonymised. Respondent validation was
used whereby previously unanticipated topics raised by
participants were added to the topic guide and discussed
with additional participants as interviewing and analysis
progressed.39 For example, changes to the PIS suggested
by parents during the initial focus group were presented
by KW during subsequent interviews for discussion and
review.40 41 To assist this process, KW reviewed early tran-
scripts and the developing coding framework and dis-
cussed these in meetings with members of the
CONNECT advisory group (LF and BY) and the EcLiPSE
development team (RA, CG, HH, SM and AI).42
Recruitment stopped when new data ceased adding to
the analysis, indicating that data saturation was
achieved.43 KW contacted parents who were not inter-
viewed (due to data saturation), explaining why their par-
ticipation in an interview was no longer required,
thanking them for their interest in the study and request-
ing their involvement in future related research. Analysis
was broadly interpretive and iterative, referring back and
forth between the developing analysis and new data for
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evidence of parents’ views on approaches to recruitment
and consent in EcLiPSE.40 41 Themes were therefore
inductively derived from the data. While the analysis was
informed by the constant comparison approach of
grounded theory, the focus was modiﬁed to ﬁt with the
criterion of catalytic validity, whereby ﬁndings should be
relevant to future research and practice.41 44 KW read
interview transcripts several times to compare within and
between transcripts.40 41 We used QSR NVivo V.10 soft-
ware to assist in the organisation and indexing of coding
and transcripts.
RESULTS
Of the 63 parent support groups contacted by tele-
phone, 14 (22%) agreed to participate and sent the
study invitation to parents by email or placed the
request on their website or Facebook page. Gatekeepers
at 8 (13%) support groups declined to participate as
they did not feel the study was appropriate for their
members. For example, their group supported parents
of children who may have died before arriving at an acci-
dent and emergency department. The remaining 41
(65%) groups did not respond to telephone messages.
Twenty-ﬁve parents registered interest in an interview.
Data saturation42 was reached at the point where 17
parents had been interviewed by telephone (11 parents:
10 mothers, 1 father) or focus group (6 parents: 5
mothers, 1 father). The 17 parents were recruited across
eight UK support groups for parents of children with
acute and chronic conditions including: meningitis,
autism, congenital diaphragmatic hernia (CHD), bronch-
omalacia, quadriplegia, acquired brain injury, epilepsy and
Dravet syndrome. Six parents (35%) were bereaved and
seven (41%) had children who had experienced a tonic–
clonic seizure. Six (35%) parents had experienced being
approached about their child taking part in a paediatric or
neonatal clinical trial (four provided consent, one
declined and one child was ineligible). The remaining six
support groups who agreed to participate did not result in
any uptake from their members.
Acceptability of deferred consent
Early in the interviews and focus group and prior to any
discussion of EcLiPSE, KW read a general deﬁnition of
deferred consent to parents:
Due to the need to treat a patient in an emergency
without delay, or parents not always being present when a
child needs treatment, it is not always appropriate or pos-
sible to obtain consent before a child is entered into a
trial. Instead UK legislation allows consent to be sought
as soon as possible afterwards. This is for permission to
use the data already collected and to continue in the
trial. This is called deferred consent. Deferred consent is
a relatively new approach to seeking consent in the UK.
KW then prompted parents to explore their prior
knowledge and views on this method of consent. Two
parents had heard of deferred consent, but neither of
them had personal experience of it. Although the
majority (n=15) were unfamiliar with this approach to
consent, they responded positively to the description.
Parents described how deferred consent was a sensible
solution to seeking consent in the emergency care
setting: it “makes sense really, doesn’t it?” (P8, telephone
interview, not bereaved). In this context, parents empha-
sised the need for research for the common good, often
describing how they supported the approach in the
emergency setting to inform the development of treat-
ments for children in the future.
It’s the right direction to go, really, because quite often,
um, you just don’t have the time or the situation, and the
data is valuable (P17, mother, telephone interview,
bereaved)
If it helps other children then that’s brilliant you know
(P9, mother, telephone interview, bereaved)
Without that data, you know, you don’t move forward (P 2,
mother focus group, not bereaved)
Many parents trusted practitioners to do the best for
their child and viewed research-related decisions as part
of the practitioners’ role in an emergency situation
when parents’ capacity to understand what was being
proposed would be limited as a result of the intense
anxiety about their child’s situation:
But then in that situation you are kind of a bit fuzzy
anyway, and you think well they know what they are
doing, so you know we sort of trust them to do their job
(P 9, mother, telephone interview, bereaved)
That [deferred consent] to me is ﬁne because it’s er
obviously based on a decision taken by doctors who are
the best people to ask, if you like, under that situation
and, and that’s a decision that they make so that’s, that’s
absolutely ﬁne, yeah, I wouldn’t have a problem with that
(P11, father, telephone interview, bereaved)
Although the majority of parents felt that deferred
consent was broadly acceptable, two parents anticipated
that they would be initially shocked or “uneasy” (P2,
focus group, not bereaved) if they were informed that
their child had been entered into a trial without their
prior consent. Views on the acceptability of deferred
consent were dependent on the nature of the trial and
the level of perceived risk parents attributed to the inter-
vention being administered. As the following focus
group excerpt illustrates, deferred consent for observa-
tion studies was viewed as more acceptable than for a
drug trial, particularly if the drug was unknown to the
parent or involved drug administration by injection.
P1 (mother, not bereaved): It depends on what exactly
they’re doing, whether they’re just taking a blood sample
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or whether they’re injecting them with something that I
don’t know, um I don’t know what it is even
P5 (father, bereaved): Whether it’s drugs or whether it’s
just sort of an easy test
P2 (mother, not bereaved): Obs (observational study,
which does not involve any intervention)
P1 (mother, not bereaved): How much risk do you want
to take?
Responses to the ECLIPSE trial
Following the general discussion of deferred consent,
KW shifted the focus to EcLiPSE. She asked each partici-
pant if they had read the EcLiPSE PIS. She then read
out key excerpts from this document including the trial
aims, a description of drugs involved, safety proﬁle and
rationale for the use of deferred consent, before
prompting parents for their responses to these aspects
of the trial. One parent described administering a drug
to a child without prior parental consent as “ethically
very difﬁcult” (P12, mother, telephone interview, not
bereaved). Most parents (n=9) expressed reservations
about EcLiPSE due to the safety proﬁle of phenytoin as
described on the information sheet. As the following
focus group excerpt illustrates, these parents were ini-
tially shocked at hearing about the side effects of pheny-
toin and discussed how these stood out from other
information provided on the sheet and had caused
alarm:
P4 (mother, not bereaved): I’d be, I’d be scared if
they’ve written, ‘Very serious unpleasant side effects’ part
P5 (father, bereaved): Yeah
P6 (mother, not bereaved): It really hits you, doesn’t it,
that?
P4 (mother, not bereaved): It does, yeah
However, parents’ opinions about the trial and its use
of deferred consent appeared to change after KW
explained how phenytoin (which is the drug associated
with the serious side effects that parents had expressed
concern about) is currently used in clinical practice and
that outside of EcLiPSE this drug would be the standard
treatment for prolonged seizures. Although the point
that phenytoin was in routine use had already been avail-
able to parents on the PIS, it was not until KW verbally
reiterated this information, and explained that the aim
of the trial was to see whether or not levetiracetam is a
more effective alternative phenytoin, that parents’ initial
concerns appeared to subside.
Facilitator: What would your initial thoughts be about
this trial?
P 14 (mother, not bereaved): I think I’d be a bit scared...
Facilitator: …So your child would have received pheny-
toin routinely if the seizures had not stopped. This can
cause very unpleasant and serious side-effects. Studies of
levetiracetam in adult emergency situations suggest that it
may be an alternative rescue medicine to phenytoin.
There have been no major side effects reported with the
use of levetiracetam. So that’s sort of why they’re doing
the trial. It’s to see if this drug, which some hospitals are
using, might be better than phenytoin, which everybody’s
using and they know can have nasty side effects. Would
that help if they explained that to you a bit more?
P 14 (mother, not bereaved):Yeah, so from that point of
view, that sounds a lot better... That, that would be the
pretty much perfect explanation to make a mum turn
around and go, it’s so they’re doing everything they can
to make sure my child is safe and to try and stop any
side-effects
After KW explained that phenytoin was the standard
treatment for prolonged seizures, all parents stated that
they would have provided deferred consent for EcLiPSE.
Parents cited their strong belief in the need for research
to advance children’s emergency medicine as informing
their position: “we’re not gonna advance unless we try”
(P12, mother, telephone interview, not bereaved). Some
parents who had expressed initial concerns about the
description of drug’s side effects on the PIS went on to
indicate that they wanted a ‘truthful’ description of
potential drug side effects: “I’d rather just hear the
truth” (P5, father, focus group, bereaved). Parents there-
fore emphasised the importance of open explanation
and discussion when broaching the trial, in addition to
the written PIS. They described the content and quality
of verbal information and explanation as key in helping
parents to understand the aims and risks of the trial:
“How it’s actually explained to parents at that point will
have a huge impact” (P10, mother, telephone interview,
not bereaved).
Parents pointed to how the outcome of a child’s status
epilepticus was likely to be a key factor in how future
parents might respond to EcLiPSE when approached
about it and their willingness to provide deferred
consent. Some (n=4) suggested that if a child does not
recover or experiences serious side effects, parents could
react angrily and feel their voluntariness has been com-
promised by the use of deferred consent:
It depends, if your child is the one that has the very
serious side effects or your child is the one that it worked
for (P3, mother, focus group, not bereaved)
I suppose your sticky wicket here is if it’s helping and if
it’s not, isn’t it? (P7, mother, telephone interview,
bereaved parent)
It wouldn’t be my response...because there is nothing
that I can do, I mean I can withdraw consent all I like,
but it might make me very cross (P17, mother, telephone
interview, bereaved)
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When to approach parents for deferred consent
When asked for their views on the ‘best time’ for practi-
tioners to approach parents for deferred consent in an
emergency situation, parents suggested that this should
be done “sooner rather than later” (P1, mother, focus
group, not bereaved). However, they also recommended
that practitioners should (where possible) wait until the
child was stable before approaching parents: “obviously
when things are stable to approach the parents because
you’re in a period of calm then” (P5, telephone inter-
view, bereaved). Parents suggested that practitioners
should gauge when is appropriate for each family on a
case-by-case basis. They recommended that practitioners
should consult with someone close to the family, such as
the bedside nurse to help establish the appropriate
timing of the initial invitation.
It probably would help if you’ve got someone who’s been
quite close with the, with the family, to sort of help to
gauge whether or not it’s an appropriate time (P8,
mother, telephone interview, not bereaved)
I do genuinely feel that in 99 per cent of the cases, if it
was… if you approached them in the right way and at the
right time then there wouldn’t be a problem (P5, father,
focus group, bereaved)
Approaching bereaved parents
KW explained to bereaved parents why it was necessary
for the trial team to approach bereaved parents in
EcLiPSE:
Children who receive emergency care are often very
poorly and sadly some will not survive. Sometimes a child
has been entered into a trial before they had passed away
and the doctor or nurse would then come and talk to
the parents to see how they feel about consenting for
their child’s data to be included in the trial. The reason
they ask bereaved parents for deferred consent is because
without including all children, trial ﬁndings won’t
provide a full picture of how safe or effective a drug is.
The ﬁndings will be biased. Doctors and nurses want to
understand what it is like for parents in this situation and
whether they should approach them about the trial
KW then asked bereaved parents for their views on
approaching parents for consent for a child’s data to be
included in EcLiPSE after the child had died. All but
one of these six parents indicated that parents should be
approached for deferred consent. The parent who
expressed reservations described how approaching
bereaved parents in this situation would add to their
grief: “my child’s gone, yeah, I’m grieving. I don’t want
you to send me a letter and remind me of something
you were doing when I was in that bad place” (P7,
mother, telephone interview, bereaved). The remaining
parents explained how they would wish to be provided
with the opportunity for their child’s data to be used in
the study. Many described how they strongly supported
medical research to inform research for the common
good and to help prevent other parents from experien-
cing a child’s death.
If it helps another child in the future, then all the better
you know...it happened so why not use the, whatever
information you gained from it to help somebody else.
And I think the people that I know that are bereaved
would probably feel pretty much the same (P9, mother,
telephone interview, bereaved)
You basically want to do everything you can to stop it
from happening to anyone else really (P17, mother, tele-
phone interview, bereaved)
Bereaved parents described the individuality of grief
and how this posed difﬁculties in making broad recom-
mendations that would be appropriate for all bereaved
parents. However, many (n=5/6) explained that
approaching parents for consent after a child’s death,
whether it be conducted by letter, telephone or in
person, should not be too soon after death “they have to
be um not just straight in there, er they would leave…
would have to leave it at the time” (P11, father, tele-
phone interview, bereaved). Parents recommended that
a doctor or nurse known to the family should broach
the subject and emphasised the considerable care and
sensitivity that an approach to parents in such circum-
stances would demand. Again, parents emphasised how
practitioners should individually gauge each situation to
establish when it is appropriate to approach each indi-
vidual family. As the following quotes illustrate, parents
acknowledged that practitioners approaching parents in
this situation should be aware that parent’s responses
may be unpredictable due to the grief they would be
suffering:
You have to understand that you’re dealing with a com-
pletely irrational time, and there’s no, nothing really
makes sense and nothing is logical… so I think it has to
be approached with care, but I mean, I, I certainly
wouldn’t mind it (P 17, mother, telephone interview,
bereaved)
I don’t even know if there is a right way, because even,
you know, how someone would talk to me, and how
someone would talk to my husband, we would both react
completely different (P9, mother, telephone interview,
bereaved)
Some you wouldn’t, you wouldn’t approach at all, but I
think you have to leave that to the discretion of the
nurse” (P11, father, telephone interview, bereaved)
Five bereaved parents described how practitioners
seeking deferred consent should be prepared to address
potential concerns from parents that the interventions
administered as part of the trial may have contributed to
their child’s death:
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It might have contributed to making them even more
poorly than they actually were, obviously you wouldn’t,
you wouldn’t be very happy about that (P5, father, focus
group, bereaved).
Terminology and written information
Parents spoke of how the EcLiPSE PIS (see appendix A,
web only ﬁle) was generally clear: “I don’t think there’s
anything that’s particularly confusing on there” (P8, tele-
phone interview, not bereaved) and the correct length for
the emergency care setting: “You don’t want a really big
sheet to have to sit and read through when your child’s
not very well anyway so I think what’s in it is enough for,
for what you’d need to know” (P13, mother, telephone
interview, not bereaved). However, they also pointed to
particular medical terms in the PIS, which they felt would
be a potential barrier to parent–practitioner communica-
tion and parental understanding of trial information.
Parents recommended simplifying some of the medical
language and viewed this as important to help parents
understand the trial information when faced with it in a
stressful emergency care situation. However, at the same
time, parents indicated that there was a linguistic balance
to be struck and that it was important to avoid language
that might be perceived as patronising.
It’s worded in a way that might go over people’s heads,
particularly if they’re in a distressed state… Not a
dummy’s guide ’cause that, that’s just really insulting but
basically make it a lot, lot simpler and not so medicalised
(P12, mother, telephone interview, not bereaved)
Parents of children with epilepsy who were familiar
with the trial drugs recommended the use of the brand
name Keppra rather than the generic name levetirace-
tam, as this was the name they used and would recognise
if presented with the PIS: “I can never pronounce that
so I call it the brand name, which is Keppra” (P9,
mother, individual interview, bereaved). Changing from
generic drug names to brand names was also recom-
mended by several other participants whose children did
not have seizures, as they also found the generic names
difﬁcult to pronounce: “I hate it when doctors call drugs
by their full name, I want to hear the brand name
because that’s what I know and that’s what I can say”
(P10, mother, telephone interview, not bereaved).
Parents also suggested changes to sentence structure in
the PIS and requested an improved explanation to
clarify that both medicinal products had previously been
used to effectively treat children: “there probably needs
to be more of a paragraph about how both of the drugs
that are in the trial erm have been used erm success-
fully” (P4, mother, focus group, not bereaved) and the
need for legal information on what parents should do if
they have a complaint: “you could have legal action”
(P6, mother, focus group, not bereaved). We provide ori-
ginal and revised (when interviews were complete) ver-
sions of the PIS (see appendices A and B, web only
ﬁles) to illustrate how the ﬁndings of the qualitative
study informed the development of this document.
DISCUSSION
We believe EcLiPSE is the ﬁrst UK trial comparing inves-
tigational medicinal products to propose a deferred
consent approach since this approach was legislated in
2008.11 Our ﬁndings provide insight into the views of
parents experienced in this setting. The majority of
parents in our sample were unfamiliar with deferred
consent, yet responded positively to a general descrip-
tion of the method. When discussing deferred consent
generally, parents questioned their capacity to provide
an informed consent decision when their child was
ill.4 45 They described how they trusted practitioners to
make research-related decisions on their behalf and
viewed deferred consent as an appropriate way to seek
consent in emergency situations and thereby enable the
future development of interventions to treat critically ill
children.46 In this context, parents indicated that study
and intervention type, safety information and route of
administration impacted on their views on the accept-
ability of the consent method. From a parent’s perspec-
tive, these factors could all be seen as markers of risk
related to their child’s participation in the trial. Indeed,
parents viewed observational studies as safer than trials
of medicinal products and therefore a more acceptable
study type to use deferred consent. For a few parents,
trials that involved unfamiliar drugs also raised concerns
about child safety. These ﬁndings helped to inform the
design of EcLiPSE, the PIS and the consent-seeking
process.
When the focus of the discussion moved to the speci-
ﬁcs of EcLiPSE and the use of deferred consent in this
trial, parents questioned the acceptability of deferred
consent in this context and many expressed initial shock
and concern about the safety of the trial linked to the
description of drug risks provided on the PIS. However,
when KW read and discussed sections of the information
sheet related to parents’ priority for safety and anxieties
about risk (eg, information related to safety and that
both drugs were used as part of routine clinical prac-
tice), parents appeared to be reassured. After this tai-
lored explanation, most parents indicated that they
would be willing to provide deferred consent for their
child’s participation in EcLiPSE, as they wished to con-
tribute to advances in medical research. There are
several potential explanations for this marked switch in
parents’ views. Although parents stated that they had
read the one page PIS before the interview, they may
not have fully read or understood it,47 48 so they were
unclear that both drugs had previously been used effect-
ively to stop tonic–clonic seizures. The content of the
PIS may have been insufﬁcient. For example, the use of
the word ‘routinely’ may be inadequate to convey how
the drugs had previously been used in clinical practice.
However, it was arguably the interviewer’s explanation of
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how phenytoin was the standard treatment for pro-
longed seizures that appeared to focus parents’ attention
on aspects of the trial which addressed their priorities
and concerns,49 namely a child’s safety. Our ﬁndings
highlight how trial practitioners need to discuss50 poten-
tially threatening information with parents to identify
their priorities49 and clarify related aspects of written
trial information to assist understanding and decision-
making. As parents may struggle to voice their concerns
in recruitment discussions with practitioners,51 these
qualitative ﬁndings will be used to inform EcLiPSE
recruiter training. Training will focus on helping practi-
tioners to identify and respond to parents’ priorities,50 52
and include the use of open-ended questions and
prompts.21 49
In line with our previous ﬁndings from the wider
CONNECT study, which investigated practitioners’ views
on deferred consent in this setting,25 the timing of the
recruitment discussion may impact on parental
responses to the method of consent. Parents, particularly
those who had been bereaved, emphasised the need for
practitioners to gauge when it is appropriate to discuss
the trial. Consultation with the clinical team may help
practitioners establish appropriate timing for a trial dis-
cussion. Our ﬁndings add to the existing literature,
which suggests that bereaved parents do wish to be
informed about a trial in the aftermath of their child’s
death,53 while serving as a reminder that a minority of
parents feel such disclosure could add to their grief.
Although we would emphasise that it is very unlikely that
children treated in EcLiPSE will die in status epilepticus
(<1% mortality rate),31 our ﬁndings will inform
approaches to consent with this vulnerable group of
parents. Our ﬁndings draw further attention to the need
for care in gauging when to explain to bereaved parents
that some of their child’s treatment had been adminis-
tered as part of a trial and to seek their consent for the
child’s data to be used in the analyses. Parents cautioned
that some time should be allowed to elapse following a
child’s death and that the approach should be con-
ducted by a nurse or doctor known to the family.
Importantly, our ﬁndings also indicate the highly vari-
able and unpredictable nature of grief following the
death of a child and how practitioners need to be
allowed to use their judgement to accommodate the
needs of individual parents. The EcLiPSE protocol will
be developed to facilitate practitioners in assessing each
family individually and to initially obtain information on
how the family is coping from colleagues and bereave-
ment counsellors before making a decision about
whether or not and when to contact a family. However,
further research is required to explore potential con-
ﬂicts of interest or privacy issues when practitioners seek
information from colleagues about the coping of
bereaved families. Our ﬁndings suggest that decisions to
approach for consent should be balanced against the
potential burden that a recruitment discussion may pose
to parents who are already emotionally and
psychologically distressed, and the likelihood that it will
be very difﬁcult for practitioners to ascertain if and
when it is appropriate to approach such vulnerable fam-
ilies when seeking deferred consent for all families,
EcLiPSE practitioners should explore parents’ views of
the trial and be prepared to respond to parents who are
concerned that participation may have been a contribut-
ing factor in their child’s death or poor recovery. These
ﬁndings are relevant to other paediatric and neonatal
clinical trials in this setting. As it is unlikely that children
treated in EcLiPSE will die, excluding bereaved parents
without obtained deferred consent is unlikely to impact
on trial ﬁndings. However, it is important to acknow-
ledge that the exclusion of this group of children may
jeopardise study results54 for emergency care trials that
experience higher rates of mortality.
To assist understanding and parent–practitioner com-
munication, parents emphasised the need for simple
and clear information, without oversimpliﬁcation. This
linguistic balance may be difﬁcult for trial teams to
achieve without input from parents or patients.55 We
amended the language used in the PIS, removing the
repetition of medical terminology and using brand
names rather than generic names for medicinal pro-
ducts (appendix B, web only ﬁle). We also removed the
word ‘routinely’ from the PIS and used our ﬁndings to
improve the written explanation that both trial drugs
were commonly used in clinical practice. Parents indi-
cated that a one page PIS was of sufﬁcient length and
that they would not wish to read much more than this
when their child was ill. These ﬁndings conﬁrm those
from other trials that have indicated that the PIS should
be short, and add to these ﬁndings by providing insights
on what parents regard as user-friendly language.56
Parents also approved the open and comprehensive
description of drug risks in the PIS. Therefore, the
description of drug risks for phenytoin was not changed
in the redrafted information sheet (see appendices A
and B, web only ﬁle).
Strengths, limitations and implications
Our ﬁndings provide insights to help practitioners when
seeking deferred consent in the paediatric emergency
care setting. As with many qualitative studies, our sample
was relatively small; however, data saturation was
reached,42 and we involved parents of children with a
range of acute and chronic health conditions who had
experience of the emergency care setting. Our ﬁndings
may therefore be transferable to other trials that
propose a deferred consent approach in paediatric
emergency care. Little is known about what practitioners
should do in the event that a child dies before deferred
consent is sought.57 These ﬁndings contribute to this
important and under-researched area and demonstrate
the value of using qualitative methods in helping to
make challenging clinical trials more family or patient
centred.21 58
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As we wanted to use the ﬁndings to inform the design
of a future trial, inevitably the trial was hypothetical at
this stage. Not all parents in our sample had children
who had experienced the particular condition (CSE)
that is the focus of EcLiPSE. To enable the successful
but sensitive recruitment of bereaved parents, we did
not restrict inclusion to parents of children who had
died of CSE, or restrict eligibility by time since death.
Nevertheless, our sampling of such parents was designed
to reﬂect the variation in the experience of parents
whose children are likely to participate in EcLiPSE. Our
sample is likely to comprise parents with an interest in
research who may be more easily reassured than the
wider population of parents. This interest in research
may not reﬂect the potential EcLiPSE sample. As part of
the wider CONNECT study, we have found that views on
deferred consent differed depending on whether or not
the practitioners were experienced in this consent
method.25 Those who were not experienced held nega-
tive preconceptions of deferred consent, whereas those
who had experience of the method were receptive to
the method, describing how deferred consent had
improved recruitment, parental decision-making and
parent–practitioner relationships in this challenging
setting. Further research will be conducted with parents
who are actually approached for deferred consent when
EcLiPSE recruitment begins, to explore whether their
responses differ from the views of parents in this sample.
This work will aim to include parents of children who
die before consent for EcLiPSE is sought. Research
embedded within trials will also help to explore whether
parental responses to recruitment vary depending on
how well their child recovers. Findings from research to
explore the views of parents approached for deferred
consent when EcLiPSE recruitment begins will be incor-
porated into trial information and practitioner training
as part of an iterative process40 41 to inform trial recruit-
ment and approaches to consent in this challenging
trial.
Children were not involved in our study. Research is
required to explore their views on the use and appropri-
ateness of deferred consent in emergency care trials.
Involving children experienced in deferred assent may
be challenging, as there are few UK trials which have
used this method,25 and assent may not have been
sought if a child was recovering or still sedated at the
point of recruitment discussion with parents. Moreover,
it is highly unlikely that children will have knowledge of
trial participation if parents have not informed them.59
Most UK funding bodies, including the National
Institute for Health Research (NIHR), require PPI with
the aim of advancing research, including its design,
conduct and dissemination.60 PPI is a prerequisite for
funding; it refers to patients and the public working as
research partners or contributing advice on whether
and how research is designed and conducted. Currently,
PPI often involves a small number of PPI representatives,
who have been selected in a variety of ways and whose
experience may not be relevant to a particular trial,
acting as coapplicants and steering group members and
contributing to decisions about the trial design. For
EcLiPSE, we felt that a qualitative study was necessary in
addition to PPI to ensure that the trial was informed by
systematic exploration and analysis of the perspectives of
a diverse group of parents, whose experiences were per-
tinent to the trial. This provided insight into how
parents may view EcLiPSE when they are approached
about it and helped us to identify strategies to enhance
recruitment and parent understanding.28 61 We antici-
pate that this insight could not have been achieved
through the involvement of PPI representatives alone.
However, qualitative research requires funding and sufﬁ-
cient time for the development of research protocols,
ethical review procedures, as well as to recruit partici-
pants, and to collect, analyse and interpret the data.
Funding opportunities for this type of research are
limited. UK funding bodies should consider how best to
resource qualitative research to inform the design of
challenging trials at the pre-trial stage to ensure that
trials are feasible and more patient or family centred.
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